BRAF and colorectal carcinoma: Second, while our study suggests potential therapeutic strategies targeting DNA methylation to suppress WNT pathway activation in BRAF-V600E mutant CRC, further preclinical work in PDOs and mouse models is needed to confirm the generic efficacy of such approaches in BRAF-V600E mutant CRC.